Abstract 497P
Background
Immune checkpoint inhibitors (ICIs) has been shown to be effective and has become the standard of care as first-line treatment of advanced NSCLC. Multiple previous studies of tumors have allowed the continued use of anti-PD-1 antibody therapy after first-line treatment progress. Subgroup analyses of these studies showed that 13-33% of patients receiving anti-PD-1 antibody therapy after progress achieved partial response (PR). The combination of ICIs and anti-angiogenic therapy has a synergistic anti-tumor effect and can improve the prognosis of patients. This study was designed to evaluate the efficacy and safety of sintilimab in combination with anlotinib in NSCLC disease progressed after first-line treatment with anti-PD-1 antibody.
Methods
An open, single-arm, phase II trial was designed, which enrolls NSCLC patients with disease progression after first-line treatment with anti-PD-1 antibody. Sintilimab (200 mg, day 1) in combination with anlotinib (12mg, day 1 to 14) were given every 3 weeks. Primary end point is objective response rate (ORR) evaluated via RECIST 1.1. Key secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety (CTCAE 5.0).
Results
From 3/2021 to 6/2023, 17 patients were enrolled. The median age was 63 years old (range 45-73) and 100% (17/17) was male. In 14 patients with efficacy data, 14.3% (2/14) achieved partial response (PR) and 71.4% (10/14) achieved stable disease (SD). ORR and DCR were 14.3% (and 85.7%, respectively. Until the last follow-up, the median PFS was 6.0 months(95% CI, range 4.2-7.7 months), 6-month PFS rate was 56.4%. The median OS was 17.9 months(95% CI, range 5.6-NA months), 12-month OS rate was 64.6%. Grade 3/4 treatment-related adverse events (TRAEs) included: hand and foot skin reaction (5.9%, 1/17), increased alanine aminotransferase (5.9%, 1/17), hypertension (11.8%, 2/17), hypertriglyceridemia (5.9%, 1/17) and neutropenia (5.9%, 1/17). No treatment-related deaths occurred.
Conclusions
Given the encouraging anti-tumor activity and favorable tolerability, the combination of sintilimab and anlotinib could be an effective and safe option for NSCLC.
Clinical trial identification
Clinical trial information: NCT04691388.
Editorial acknowledgement
Legal entity responsible for the study
Xinmin Yu.
Funding
1. Innovent Biologics, Inc. 2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract